class I molecules. At the time, however, it was unknown whether cross-presentation was physiologically important or just an epiphenomenon. Indeed, we didn't even know how CD8 T-cell responses to viruses were initiated. Using bone marrow chimeras and the poxvirus vaccinia virus (VACV, the smallpox vaccine), we showed that only cells of hematopoietic origin can initiate antiviral CD8 T-cell responses (we later extended this to other viruses), and by collaborating with Raul Andino, an Argentinean virologist specialized in poliovirus, we used mice transgenic for the human poliovirus receptor and Raul's recombinant polioviruses to show that when hematopoietic cells cannot be infected, they use cross-presentation to take up viral antigens from other infected cells, thereby initiating the antiviral CD8 T-cell response.
My postdoctoral work with Ken made a splash and opened the door to establish my own lab at Fox Chase Cancer Center in Philadelphia as an assistant professor. I initially focused on solving some outstanding issues in cross-presentation using VACV, for which I rapidly obtained NIH funding. Yet the project was too much into cell biology, which was not what my research passions were. About 2 years after establishing my lab, at a small symposium in Madrid, Spain, I heard presentations by Antonio Alcami and Guna Karupiah on a poxvirus of the mouse known as Ectromelia virus (ECTV). This virus causes mousepox, a disease similar to human smallpox in some strains of mice but not others and, similar to smallpox, can be prevented by immunization with VACV. I immediately became hooked because ECTV offered a tractable model to study the genetic control of viral disease and to understand how a well-established vaccine protects a natural host. I made the risky move to start a new project in an area in which I had no experience, but I was lucky that the move paid off. Within a few years, I established a strong and well-funded research program using ECTV to understand fundamental problems in viral immunology. Using ECTV, my research team, now at Thomas Jefferson University in Philadelphia, has studied many different aspects of genetic, age-related, and vaccine-induced resistance to viral diseases, including the role of various mechanisms of host innate and adaptive immunity, as well as slick immune evasion countermeasures by the virus. So far, my scientific career has been an exhilarating adventure that I believe made important contributions to our understanding of the pathogenesis and immunology of viral infection, the very same interests that brought me into science when I was a young but bored veterinarian.
